2 unchanged sentences
filed a lawsuit against Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC (collectively, Padagis) in the U.S.
−Removed: District Court for the District of Delaware on March 27, 2024, based on the submission to the FDA of an ANDA seeking approval to market and sell a generic version of Arcutis’s ZORYVE® 0.3% cream for the treatment of plaque psoriasis.
+Added: District Court for the District of Delaware on March 27, 2024, based on the submission to the FDA of an Abbreviated New Drug Application (ANDA) seeking approval to market and sell a generic version of Arcutis’ ZORYVE® 0.3% cream for the treatment of plaque psoriasis.
The Company asserts infringement of the following eleven patents, which are listed in the FDA’s Orange Book for Arcutis’ ZORYVE® 0.3% cream:
6 unchanged sentences
On August 2, 2024, Padagis responded to the first amended complaint, denying infringement and asserting counterclaims seeking a declaratory judgement that the asserted patents are not infringed, invalid, and/or unenforceable.
−Removed: The court issued a scheduling order on June 10, 2024, which sets trial at the court’s convenience, or around April 13-17, 2026.
−Removed: The automatic 30-month stay of FDA approval of Padagis’s ANDA seeking approval for Arcutis’s ZORYVE® 0.3% cream is set to expire on August 14, 2026.
+Added: On April 3, 2025, the court stayed the case and cancelled all case deadlines, including the trial.
+Added: The automatic 30-month stay of FDA approval of Padagis’s ANDA seeking approval for Arcutis’s ZORYVE® 0.3% cream was set to expire on August 14, 2026.
+Added: The 30-month stay will be extended for each day the stay is in place, starting March 24, 2025 until the stay is lifted.
+Added: Teva Pharmaceutical Industries Ltd.
+Added: filed Oppositions with the European Patent Office against two of our European patents, European Patent Nos.
+Added: EP 3634380 B1 and EP 3684334 B1, on September 20, 2024 and August 13, 2024, respectively.
+Added: These patents relate to topical roflumilast compositions.
+Added: Arcutis filed replies on February 24, 2025, and January 23, 2025, respectively.
+Added: On February 19, 2025, Arcutis received Teva’s reply to Arcutis’s January 23, 2025 submission for EP 3684334 to which Arcutis filed an additional reply on April 16, 2025.
+Added: Hearings before the EPO’s Opposition Division are not yet scheduled and the proceedings are ongoing.
We may from time to time be involved in various legal proceedings of a character normally incident to the ordinary course of our business.
We are not currently a party to any material litigation or other material legal proceedings.
+Added: For a discussion of our potential risks and uncertainties, see the information in Part I, "Part I, Item 1A.
+Added: Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024.
+Added: There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024.
+Added: UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
+Added: Issuer Purchases of Equity Securities
+Added: DEFAULTS UPON SENIOR SECURITIES
+Added: MINE SAFETY DISCLOSURES
+Added: Not applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.